Putin sees Russia becoming world’s largest LNG producerBusiness & Economy March 30, 17:58
UK media comes up with more ‘fake news’ about Russian football fansSport March 30, 17:49
Original images vs. portraits on canvas: An artist's eye versus the camera lensSociety & Culture March 30, 17:24
Putin thanks CNBC anchor for correctly setting Crimea apart from UkraineRussian Politics & Diplomacy March 30, 16:57
Putin says no plans to restrict rocket engine supplies to USScience & Space March 30, 16:49
Russia’s Space Force deploys high-tech space monitoring systemsMilitary & Defense March 30, 16:25
Putin stresses Russia’s military activities in Arctic threaten no oneRussian Politics & Diplomacy March 30, 16:18
Russia and Norway team up to clean Arctic of nuclear wasteWorld March 30, 16:10
Putin: Corruption must be fought against, but using this issue to score points is wrongRussian Politics & Diplomacy March 30, 16:07
DARMSTADT, Germany, June 7, 2016 /PRNewswire/. Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by Merck, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis. Findings will be presented on June 8 at the 2016 BIO International Convention in San Francisco, California.
Photo - http://photos.prnewswire.com/prnh/20160602/374903
"In response to the uncertainty and disruption facing the biopharmaceutical industry, Merck has moved beyond old risk-management models and has adopted and is applying new strategies at the earliest stages of development and seeing them through to commercialization," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Study highlights include:
Manufacturers in the biopharma industry face unprecedented challenges as they enter unfamiliar geographies, aggressively replenish pipelines and expand into novel areas such as gene and cell therapies requiring more complex development and production. The EIU study, detailed in The Changing Biopharma Risk Equation, examines how new growth strategies are creating exposure to different types of risk and explores options for successfully navigating this unexplored territory.
Survey respondents offered a global view with 31 percent from Europe, 30 percent from North America, 29 percent from Asia and 10 percent from the rest of the world. Responses also reflect the differences in view depending on company size, with 50 percent of participants coming from biopharmas with less than $500 million in revenues and 50 percent from larger players.
To download the report, access additional content on the changing nature of biopharma and explore how Merck can help companies go beyond the changes and challenges facing the industry, visit www.gobeyondbiopharma.com.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of €12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
CONTACT: Karen Tiano, +1 978 495 0093